Allarity Therapeutics, Inc. ALLR 深 沪
已收盘 05-22 16:00:00 美东时间
1.77
+0.110
+6.63%
华盛通- 最 高1.78
- 今 开1.66
- 成交量 31.65万股
- 最 低 1.55
- 昨 收 1.66
- 总市值 2816.20万
- 52周最高 2.35
- 市盈率 静 --
- 换手率 1.99%
- 52周最低 0.7687
- 委 比 -96.61%
- 总股本 1591.07万
- 历史最高 15288000.00
- 量 比 1.20
- 振 幅 13.86%
- 历史最低 0.6138
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Allarity Therapeutics Q1 EPS $(0.17) Beats $(0.22) Estimate, Sales $25.000K
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 32 percent increase over losses of $(0.25) per share
05-16 04:31
Allarity Therapeutics shares are trading higher after the company announced that its active pharmaceutical ingredient manufacturing campaign for stenoparib is progressing in line with the planned timeline for completion, no later than Q3 of 2026, at its world-class contract development and manufacturing organization.
Allarity Therapeutics shares are trading higher after the company announced tha...
05-06 00:16
美股大行评级 | 大砍54%！大摩下调Robinhood 目标价从147降至95美元；星座品牌酒业(STZ)获8家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9.5美元升至9.75美元；Citizens：维持戴夫"跑赢大市"评级，目标价从310美元升至335美元
04-13 14:07
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.75
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $9.5 to $9.75.
04-10 17:34
Allarity Therapeutics Q4 EPS $(0.21), Inline, Sales $320.000K
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 87.79 percent increase over losses of $(1.72) per share from the same period last
03-31 22:24
Allarity Therapeutics Closes $20M Non-Convertible Debt Funding With Streeterville Capital; Expects Cash Runway To Support Operations Through Mid-2028
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway
03-06 21:11
Allarity Therapeutics Starts Enrollment For Phase 2 Trial To Developing Senoparib
This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S.
02-03 21:09
Allarity Therapeutics Files Prospectus To Offer Up To $50M In Various Securities
Allarity Therapeutics, Inc.$50,000,000Common StockPreferred StockDebt SecuritiesWarrantsRightsUnits We may from time to time, in one or more offerings, offer and sell up to $50,000,000 in the aggregate of the
2025-12-03 22:14
Allarity Therapeutics Q3 EPS $(0.19) Beats $(0.21) Estimate
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 97.54 percent increase over losses of $(7.71) per share
2025-11-14 22:11
